Early Type News Today

Hosts discuss a recent study on baricitinib in type 1 diabetes, how these results compare to other data in this arena, and what all of these studies mean for future of type 1 diabetes management.

An overview of the journey and significant events of 2023 that have catapulted semaglutide from a type 2 diabetes agent to the topic of discussions among circles across healthcare and beyond.

An obesity doctor and endocrinologist weigh in.

Early onset of type 2 diabetes can reduce life expectancy by up to 14 years, highlighting the urgency for preventive measures.

A case series of 10 patients with newly diagnosed type 1 diabetes provides insight into the beneficial effects of off-label semaglutide use on insulin use, HbA1c, and fasting C-peptide levels among this patient population.

Treating newly diagnosed Type 1 diabetes patients with semaglutide (trade names Ozempic, Wegovy and Rybelsus) may drastically reduce or even eliminate their need for injected insulin. Those are the remarkable findings of a small University at Buffalo study reported in the New England Journal of Medicine and published online on Sept. 6.